Skip to main content

Immunotherapeutic targeting of Wilms' tumor protein.

Publication ,  Journal Article
Hutchings, Y; Osada, T; Woo, CY; Clay, TM; Lyerly, HK; Morse, MA
Published in: Curr Opin Mol Ther
February 2007

The expression of Wilms' tumor protein (WT1)-derived peptides on malignant cell surfaces and recognition of those peptides by cellular and humoral immune responses suggest that WT1 may be a promising potential target antigen in immunotherapeutic trials. With a high frequency of expression in hematopoietic as well as solid tumors, WT1 is a broadly applicable target. Both in vivo mouse model and in vitro human studies have demonstrated the ability of WT1-specific cytotoxic T-lymphocytes to lyse WT1-expressing malignancies without harming normal tissue. WT1-peptide vaccination, in combination with adjuvants, has demonstrated the ability to activate WT1-specific immune responses and evidence of clinical activity. Because peptide-based vaccines are human leukocyte antigen-restricted, other more broadly applicable strategies are now being developed to activate WT1-specific immune responses, including the use of WT1-specific viral vectors.

Duke Scholars

Published In

Curr Opin Mol Ther

ISSN

1464-8431

Publication Date

February 2007

Volume

9

Issue

1

Start / End Page

62 / 69

Location

England

Related Subject Headings

  • Wilms Tumor
  • WT1 Proteins
  • Immunotherapy
  • Humans
  • Histocompatibility Antigens Class II
  • Histocompatibility Antigens Class I
  • Clinical Trials as Topic
  • Biotechnology
  • Animals
  • 3206 Medical biotechnology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hutchings, Y., Osada, T., Woo, C. Y., Clay, T. M., Lyerly, H. K., & Morse, M. A. (2007). Immunotherapeutic targeting of Wilms' tumor protein. Curr Opin Mol Ther, 9(1), 62–69.
Hutchings, Yalonda, Takuya Osada, Christopher Y. Woo, Timothy M. Clay, H Kim Lyerly, and Michael A. Morse. “Immunotherapeutic targeting of Wilms' tumor protein.Curr Opin Mol Ther 9, no. 1 (February 2007): 62–69.
Hutchings Y, Osada T, Woo CY, Clay TM, Lyerly HK, Morse MA. Immunotherapeutic targeting of Wilms' tumor protein. Curr Opin Mol Ther. 2007 Feb;9(1):62–9.
Hutchings, Yalonda, et al. “Immunotherapeutic targeting of Wilms' tumor protein.Curr Opin Mol Ther, vol. 9, no. 1, Feb. 2007, pp. 62–69.
Hutchings Y, Osada T, Woo CY, Clay TM, Lyerly HK, Morse MA. Immunotherapeutic targeting of Wilms' tumor protein. Curr Opin Mol Ther. 2007 Feb;9(1):62–69.

Published In

Curr Opin Mol Ther

ISSN

1464-8431

Publication Date

February 2007

Volume

9

Issue

1

Start / End Page

62 / 69

Location

England

Related Subject Headings

  • Wilms Tumor
  • WT1 Proteins
  • Immunotherapy
  • Humans
  • Histocompatibility Antigens Class II
  • Histocompatibility Antigens Class I
  • Clinical Trials as Topic
  • Biotechnology
  • Animals
  • 3206 Medical biotechnology